MedTrace Logo

Evaluation of A Clinical Diagnostic Test for CRDS

NCT06188689 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-05-05

No results posted yet for this study

Summary

Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.

Conditions

  • Calcium Release Deficiency Syndrome (CRDS)

Interventions

DIAGNOSTIC_TEST

Pacing

1. Ventricular 10 beat burst at 500ms (120bpm) 2. Ventricular 10 beat burst at 400ms (150bpm) 3. Atrial 10 beat burst at 500ms (120bpm) 4. Atrial 10 beat burst at 400ms (150bpm).

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Ziv Dadon, MD · Shaare Zedek Medical Center

  • Jason D Roberts, MD MAS · McMaster University

  • Wayne Chen, PhD · University of Calgary

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2027-12-31
Completion
2028-03-31

Countries

  • United States
  • Belgium
  • Canada
  • Denmark
  • France
  • Israel
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06188689 on ClinicalTrials.gov